Literature DB >> 12378569

A first trimester trisomy 13/trisomy 18 risk algorithm combining fetal nuchal translucency thickness, maternal serum free beta-hCG and PAPP-A.

Kevin Spencer1, Kypros H Nicolaides.   

Abstract

This study examines 45 cases of trisomy 13 and 59 cases of trisomy 18 and reports an algorithm to identify pregnancies with a fetus affected by trisomy 13 or 18 by a combination of maternal age fetal nuchal translucency (NT) thickness, and maternal serum free beta-hCG and PAPP-A at 11-14 weeks of gestation. In this mixed trisomy group the median MoM NT was increased at 2.819, whilst the median MoMs for free beta-hCG and PAPP-A were reduced at 0.375 and 0.201 respectively. We predict that with the use of the combined trisomy 13 and 18 algorithm and a risk cut-off of 1 in 150 will for a 0.3% false positive rate allow 95% of these chromosomal defects to be identified at 11-14 weeks. Such algorithms will enhance existing first trimester screening algorithms for trisomy 21. Copyright 2002 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12378569     DOI: 10.1002/pd.420

Source DB:  PubMed          Journal:  Prenat Diagn        ISSN: 0197-3851            Impact factor:   3.050


  13 in total

1.  First-trimester combined screening is effective for the detection of unbalanced chromosomal translocations at 11 to 12 weeks of gestation.

Authors:  Shangyu Huang; Chialin Chang; Pojen Cheng; Chinghua Hsiao; Yungkuei Soong; Tao Duan
Journal:  Reprod Sci       Date:  2013-10-31       Impact factor: 3.060

Review 2.  First trimester ultrasound tests alone or in combination with first trimester serum tests for Down's syndrome screening.

Authors:  S Kate Alldred; Yemisi Takwoingi; Boliang Guo; Mary Pennant; Jonathan J Deeks; James P Neilson; Zarko Alfirevic
Journal:  Cochrane Database Syst Rev       Date:  2017-03-15

Review 3.  First and second trimester serum tests with and without first trimester ultrasound tests for Down's syndrome screening.

Authors:  S Kate Alldred; Yemisi Takwoingi; Boliang Guo; Mary Pennant; Jonathan J Deeks; James P Neilson; Zarko Alfirevic
Journal:  Cochrane Database Syst Rev       Date:  2017-03-15

Review 4.  Second trimester serum tests for Down's Syndrome screening.

Authors:  S Kate Alldred; Jonathan J Deeks; Boliang Guo; James P Neilson; Zarko Alfirevic
Journal:  Cochrane Database Syst Rev       Date:  2012-06-13

5.  NSGC practice guideline: prenatal screening and diagnostic testing options for chromosome aneuploidy.

Authors:  K L Wilson; J L Czerwinski; J M Hoskovec; S J Noblin; C M Sullivan; A Harbison; M W Campion; K Devary; P Devers; C N Singletary
Journal:  J Genet Couns       Date:  2012-11-22       Impact factor: 2.537

Review 6.  First trimester serum tests for Down's syndrome screening.

Authors:  S Kate Alldred; Yemisi Takwoingi; Boliang Guo; Mary Pennant; Jonathan J Deeks; James P Neilson; Zarko Alfirevic
Journal:  Cochrane Database Syst Rev       Date:  2015-11-30

Review 7.  Urine tests for Down's syndrome screening.

Authors:  S Kate Alldred; Boliang Guo; Yemisi Takwoingi; Mary Pennant; Susanna Wisniewski; Jonathan J Deeks; James P Neilson; Zarko Alfirevic
Journal:  Cochrane Database Syst Rev       Date:  2015-12-10

8.  An Economic Analysis of Cell-Free DNA Non-Invasive Prenatal Testing in the US General Pregnancy Population.

Authors:  Peter Benn; Kirsten J Curnow; Steven Chapman; Steven N Michalopoulos; John Hornberger; Matthew Rabinowitz
Journal:  PLoS One       Date:  2015-07-09       Impact factor: 3.240

Review 9.  Prenatal Screening Using Maternal Markers.

Authors:  Howard Cuckle
Journal:  J Clin Med       Date:  2014-05-09       Impact factor: 4.241

Review 10.  Maternal Serum Screening Markers and Adverse Outcome: A New Perspective.

Authors:  David Krantz; Terrence Hallahan; David Janik; Jonathan Carmichael
Journal:  J Clin Med       Date:  2014-07-03       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.